Information Provided By: 
Fly News Breaks for September 14, 2017
FOLD
Sep 14, 2017 | 08:01 EDT
Baird analyst Michael Ulz noted Amicus reported its SD-101 Phase 3 study missed all of its endpoints. Although disappointing, the trial was given a low probability of success. This news removes a key overhang for the company, setting up additional upside with its Pompe program, Ulz tells investors. He remains encouraged by the early data from the Pompe program, which should be releasing full six-month data later this month. Ulz reiterated his Outperform rating and raised his price target to $16 from $15 on Amicus shares.
News For FOLD From the Last 2 Days
There are no results for your query FOLD
